Daklinza and Sovaldi to Treat Hep C Genotype 1
FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hepatitis C Genotype 1
February 10, 2016
The U.S. Food and Drug Administration (FDA) has expanded the approved uses of the combination hepatitis C virus (HCV) regimen of Bristol-Myers Squibb’s (BMS) Daklinza (daclatasvir) and Gilead Sciences’ Sovaldi (sofosbuvir). Approved to treat genotype 3 of the virus in July 2015, the regimen may now treat genotype 1, as well as individuals with advanced cirrhosis and people whose hep C has returned after a liver transplant.
Continue reading this entire article: